UCSF home page About UCSF UCSF Medical Center
UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Decrease the text sizeRestore original text sizeIncrease the text size Enlarge Text
Click to increase the text size.
Restore Text
Click to restore original text size.
Reduce Text
Click to decrease the text size.
Transporter Database banner  
Decrease the text size | Restore text size | Increase the text size
Text Sizer image
Home About and More Information Transporter Data Index
Search:  
 

SLC10A1

Synonyms: NTCP

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ Source Relative Expression
Brain Nishimura    0.00260
Kidney Nishimura    0.00185
Liver* Nishimura    0.486
Placenta Nishimura    0.00246
Small Intestine Nishimura    0.00138
Kidney Mean across all PMT Samples    0.0470
Liver* Mean across all PMT Samples 109.897
Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate Km (μM) Cell System Reference
Cholate 12 HeLa-NTCP Ho, 2004
Estrone sulfate 27 HeLa-NTCP Ho, 2004
Glycoursodeoxycholate 0.376 HEK-NTCP Maeda, 2006
Pitavastatin 15.1 NTCP-expressing oocytes Fujino, 2005
Rosuvastatin 65 HeLa-NTCP Ho, 2006
Taurocholate 7.9 HeLa-NTCP Kim, 1999
Taurocholate 7.5 HeLa-NTCP Ho, 2004
Taurocholate 2.1 HEK-NTCP Leslie, 2007
Tauroursodeoxycholate 3.49 HEK-NTCP Maeda, 2006

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

In Vitro Inhibitors

Inhibitor IC50 (μM) Ki (μM) Substrate used Cell System Reference
(R)-propanolol 5.5 Taurocholate HeLa-NTCP Kim, 1999
(S)-propanolol 6.1 Taurocholate HeLa-NTCP Kim, 1999
Bosentan 18 Taurocholate HEK293-ASBT Leslie, 2007
Bromsulphthalein 7.3 Taurocholate HeLa-NTCP Kim, 1999
Cholate 5.3 Taurocholate HeLa-NTCP Kim, 1999
Cyclosporine 0.37 Rosuvastatin HeLa-NTCP Ho, 2006
Cyclosporine 1 Taurocholate HeLa-NTCP Kim, 1999
Furosemide 15 Taurocholate HeLa-NTCP Kim, 1999
Gemfibrozil 23 Rosuvastatin HeLa-NTCP Ho, 2006
Ketoconazole 264 Taurocholate HeLa-NTCP Kim, 1999
Tetrabromobisphenol A 4.5 Taurocholate HEK293 cells Bruyere, 2017
Ursodeoxycholate 3.6 Taurocholate HeLa-NTCP Kim, 1999

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Clinical Drug-Drug Interactions

No drug-drug interaction information.


Back to top

Contact us | Glossary

Blue banner